Empowering transformative research and healthcare with the power of proteomics
SomaLogic has revolutionized aptamer-based proteomics.
Our pioneering platform provides more coverage of the proteome than any other technology. With more coverage comes better insights, smarter decisions, improved outcomes, better healthcare. SomaLogic is an industry leader in proteomics, adding new analytes and developing innovative ways to advance your work every single day.
Discover how the world’s leading life science and pharmaceutical research organizations are transforming their discovery and validation pipelines with our groundbreaking proteomic technologies.
Real-time health information that enables health systems to make better decisions and improve outcomes across their populations.
Analyze and visualize all your studies in one clear, concise, and convenient view on the SomaLogic Life Sciences Portal. Combine study tracking with the power of statistical analysis and data visualization, and access our full menu of analytes.
Industry-leading means…
We built the first and only platform that can simultaneously measure 7,000 proteins across a wide range of concentrations. Now we’re translating those measurements into key clinical indicators of health status and risk.
Largest menu
7,000 proteins per sample
Top tier facilities
CLIA-licensed ultra high-throughput lab
Highly translational
Proteomics and clinical metrics from 55 μL of blood
Well-established
20 years of innovation, >500 patents
For insights across multiple diseases
Cancer
Accelerate your biomarker discovery with sensitive detection of 7,000 proteins from a 55-µL sample.
Cardiovascular disease
Discover multiple cardiovascular indicators from a 55-µL plasma sample.
Diabetes
The SomaScan® Assay could advise patients on lifestyle changes to help prevent the onset of type 2 Diabetes.
Neurology
Get a high-throughput, multiplex proteomics solution that focuses on the complexity of neurological diseases.
Rare disease
Advancing rare disease research with powerful protein profiling and offering new insights into biomarker discovery.